Accelerated approval will be 'the norm' for gene therapies, FDA's Peter Marks says - Endpoints

The FDA will increasingly use accelerated approval for gene therapies aimed at rare conditions, according to Peter Marks, the FDA’s top official overseeing cell and gene therapies, the clearest signal yet of how widely the agency will deploy its expedited pathway.

Read more